# Minerva Neurosciences, Inc.: financial statements, quarterly

NERV · Nasdaq · CIK 1598646 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nerv.md) · [Financials](/companies/nerv/financials.md) · [Filings](/companies/nerv/filings.md) · [Insiders](/companies/nerv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nerv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [3.4](/filings/0000950170-24-121063.md) | [4.7 d](/filings/0000950170-25-026055.md) | [4.2](/filings/0000950170-25-069780.md) | [3.9](/filings/0000950170-25-108840.md) | [1.9](/filings/0001193125-25-265685.md) | [2.0 d](/filings/0001193125-26-101117.md) | [1.4](/filings/0001193125-26-205182.md) | [1.3](/filings/0001193125-26-339171.md) | [0.9](/filings/0001193125-25-265685.md) | [2.2 d](/filings/0001193125-26-101117.md) | [5.3](/filings/0001193125-26-205182.md) | [7.2](/filings/0001193125-26-339171.md) |
| Operating income | $m | [(6.1)](/filings/0000950170-24-121063.md) | [(7.2) d](/filings/0000950170-25-026055.md) | [(6.7)](/filings/0000950170-25-069780.md) | [(6.3)](/filings/0000950170-25-108840.md) | [(4.4)](/filings/0001193125-25-265685.md) | [(4.5) d](/filings/0001193125-26-101117.md) | [(3.9)](/filings/0001193125-26-205182.md) | [(3.4)](/filings/0001193125-26-339171.md) | [(2.8)](/filings/0001193125-25-265685.md) | [(5.0) d](/filings/0001193125-26-101117.md) | [(16.7)](/filings/0001193125-26-205182.md) | [(10.6)](/filings/0001193125-26-339171.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(7.8)](/filings/0000950170-24-121063.md) | [(9.0) d](/filings/0000950170-25-026055.md) | [(8.6)](/filings/0001193125-25-265685.md) | [(8.2)](/filings/0001193125-25-265685.md) | [22.5](/filings/0001193125-25-265685.md) | [(4.3) d](/filings/0001193125-26-101117.md) | [(3.8)](/filings/0001193125-26-339171.md) | [(3.3)](/filings/0001193125-26-339171.md) | [(2.7)](/filings/0001193125-25-265685.md) | [(284) d](/filings/0001193125-26-101117.md) | [(125)](/filings/0001193125-26-339171.md) | [17.5](/filings/0001193125-26-339171.md) |
| Diluted EPS | $ per share | [(1.03)](/filings/0000950170-24-121063.md) | not reported | [(1.13)](/filings/0000950170-25-069780.md) | [(1.09)](/filings/0000950170-25-108840.md) | [2.97](/filings/0001193125-25-265685.md) | not reported | [(0.50)](/filings/0001193125-26-205182.md) | [(0.43)](/filings/0001193125-26-339171.md) | [(0.36)](/filings/0001193125-25-265685.md) | not reported | [(2.86)](/filings/0001193125-26-205182.md) | [(0.14)](/filings/0001193125-26-339171.md) |
| Basic EPS | $ per share | [(1.03)](/filings/0000950170-24-121063.md) | not reported | [(1.13)](/filings/0000950170-25-069780.md) | [(1.09)](/filings/0000950170-25-108840.md) | [2.97](/filings/0001193125-25-265685.md) | not reported | [(0.50)](/filings/0001193125-26-205182.md) | [(0.43)](/filings/0001193125-26-339171.md) | [(0.36)](/filings/0001193125-25-265685.md) | not reported | [(2.86)](/filings/0001193125-26-205182.md) | [0.36](/filings/0001193125-26-339171.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [46.9](/filings/0000950170-24-121063.md) | [40.9](/filings/0000950170-25-026055.md) | [34.8](/filings/0000950170-25-069780.md) | [30.9](/filings/0000950170-25-108840.md) | [26.5](/filings/0001193125-25-265685.md) | [21.4](/filings/0001193125-26-101117.md) | [17.3](/filings/0001193125-26-205182.md) | [15.2](/filings/0001193125-26-339171.md) | [12.3](/filings/0001193125-25-265685.md) | [82.3](/filings/0001193125-26-339171.md) | [32.7](/filings/0001193125-26-205182.md) | [24.7](/filings/0001193125-26-339171.md) |
| Current assets | $m | [48.2](/filings/0000950170-23-059747.md) | [42.0](/filings/0000950170-25-026055.md) | [35.6](/filings/0000950170-24-050883.md) | [31.4](/filings/0000950170-24-091195.md) | [27.9](/filings/0000950170-24-121063.md) | [22.3](/filings/0001193125-26-101117.md) | [17.9](/filings/0000950170-25-069780.md) | [15.5](/filings/0000950170-25-108840.md) | [13.0](/filings/0001193125-25-265685.md) | [83.1](/filings/0001193125-26-339171.md) | [79.1](/filings/0001193125-26-205182.md) | [79.7](/filings/0001193125-26-339171.md) |
| Total assets | $m | [63.1](/filings/0000950170-23-059747.md) | [56.9](/filings/0000950170-25-026055.md) | [50.5](/filings/0000950170-24-050883.md) | [46.3](/filings/0000950170-24-091195.md) | [42.8](/filings/0000950170-24-121063.md) | [37.1](/filings/0001193125-26-101117.md) | [32.8](/filings/0000950170-25-069780.md) | [30.4](/filings/0000950170-25-108840.md) | [28.1](/filings/0001193125-25-265685.md) | [98.0](/filings/0001193125-26-339171.md) | [94.0](/filings/0001193125-26-205182.md) | [95.1](/filings/0001193125-26-339171.md) |
| Current liabilities | $m | [3.3](/filings/0000950170-23-059747.md) | [3.3](/filings/0000950170-25-026055.md) | [2.8](/filings/0000950170-24-050883.md) | [4.2](/filings/0000950170-24-091195.md) | [4.5](/filings/0000950170-24-121063.md) | [2.8](/filings/0001193125-26-101117.md) | [1.9](/filings/0000950170-25-069780.md) | [2.5](/filings/0000950170-25-108840.md) | [2.7](/filings/0001193125-25-265685.md) | [2.3](/filings/0001193125-26-339171.md) | [4.5](/filings/0001193125-26-205182.md) | [4.0](/filings/0001193125-26-339171.md) |
| Total liabilities | $m | [83.2](/filings/0000950170-23-059747.md) | [85.4](/filings/0000950170-25-026055.md) | [87.1](/filings/0000950170-24-050883.md) | [90.8](/filings/0000950170-24-091195.md) | [64.5](/filings/0000950170-24-121063.md) | [62.8](/filings/0001193125-26-101117.md) | [61.9](/filings/0000950170-25-069780.md) | [62.5](/filings/0000950170-25-108840.md) | [62.7](/filings/0001193125-25-265685.md) | [234](/filings/0001193125-26-339171.md) | [343](/filings/0001193125-26-205182.md) | [297](/filings/0001193125-26-339171.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(20.0)](/filings/0000950170-24-121063.md) | [(28.5)](/filings/0001193125-26-101117.md) | [(36.6)](/filings/0001193125-25-265685.md) | [(44.5)](/filings/0001193125-25-265685.md) | [(21.7)](/filings/0001193125-25-265685.md) | [(25.7)](/filings/0001193125-26-339171.md) | [(29.1)](/filings/0001193125-26-339171.md) | [(32.1)](/filings/0001193125-26-339171.md) | [(34.6)](/filings/0001193125-25-265685.md) | [(141)](/filings/0001193125-26-339171.md) | [(254)](/filings/0001193125-26-339171.md) | [(213)](/filings/0001193125-26-339171.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.8) d](/filings/0000950170-24-121063.md) | [(6.0) d](/filings/0000950170-25-026055.md) | [(6.1)](/filings/0000950170-25-069780.md) | [(3.9) d](/filings/0000950170-25-108840.md) | [(4.4) d](/filings/0001193125-25-265685.md) | [(5.2) d](/filings/0001193125-26-101117.md) | [(4.1)](/filings/0001193125-26-205182.md) | [(2.0) d](/filings/0001193125-26-339171.md) | [(2.9) d](/filings/0001193125-25-265685.md) | [(4.5) d](/filings/0001193125-26-101117.md) | [(5.4)](/filings/0001193125-26-205182.md) | [(13.3) d](/filings/0001193125-26-339171.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [5.3](/filings/0000950170-23-059747.md) | [5.3](/filings/0000950170-24-050883.md) | [5.5](/filings/0000950170-24-091195.md) | [7.6](/filings/0000950170-24-121063.md) | [7.6](/filings/0000950170-25-069780.md) | [7.6](/filings/0000950170-25-108840.md) | [7.6](/filings/0001193125-25-265685.md) | [7.6](/filings/0001193125-26-205182.md) | [7.6](/filings/0001193125-26-339171.md) | [7.6](/filings/0001193125-25-265685.md) | [43.9](/filings/0001193125-26-205182.md) | [79.1](/filings/0001193125-26-339171.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 47,747,559 at 2026-08-04, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-339171.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.